Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)

Core Points - An investigation is underway regarding Akero Therapeutics, Inc. and its Board of Directors for potential breaches of fiduciary duties and violations of federal securities laws [1] - The investigation is linked to a proposed merger with Novo Nordisk A/S, where Akero shareholders would receive $54.00 per share in cash and a Contingent Value Right worth an additional $6.00 per share if Akero's lead product candidate, efruxifermin, receives regulatory approval by June 30, 2031 [2] Company Overview - Akero Therapeutics, Inc. is a clinical stage biopharmaceutical company based in San Francisco, focusing on developing efruxifermin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) [2]